These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 14966870)
21. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL). Cycon KA; Rimsza LM; Murphy SP Exp Hematol; 2009 Feb; 37(2):184-194. PubMed ID: 19081173 [TBL] [Abstract][Full Text] [Related]
22. TNF-alpha suppresses IFN-gamma-induced MHC class II expression in HT1080 cells by destabilizing class II trans-activator mRNA. Han Y; Zhou ZH; Ransohoff RM J Immunol; 1999 Aug; 163(3):1435-40. PubMed ID: 10415044 [TBL] [Abstract][Full Text] [Related]
23. Pathologic expression of MHC class II is driven by mitogen-activated protein kinases. Martins I; Deshayes F; Baton F; Forget A; Ciechomska I; Sylla K; Aoudjit F; Charron D; Al-Daccak R; Alcaide-Loridan C Eur J Immunol; 2007 Mar; 37(3):788-97. PubMed ID: 17304627 [TBL] [Abstract][Full Text] [Related]
24. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins. Broxmeyer HE; Cooper S; Hangoc G; Chang CH Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914 [TBL] [Abstract][Full Text] [Related]
25. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity. Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958 [TBL] [Abstract][Full Text] [Related]
26. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768 [TBL] [Abstract][Full Text] [Related]
27. Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2. Xi H; Eason DD; Ghosh D; Dovhey S; Wright KL; Blanck G Oncogene; 1999 Oct; 18(43):5889-903. PubMed ID: 10557076 [TBL] [Abstract][Full Text] [Related]
28. Inhibitor (IK) of IFN-gamma induced HLA class II antigens expression also inhibits HLA class II constitutive expression in the human Raji B cell line. Vedrenne J; Assier E; Pereno R; Bouzinba-Segard H; Azzarone B; Jasmin C; Charron D; Krief P Oncogene; 1997 Mar; 14(12):1453-61. PubMed ID: 9136989 [TBL] [Abstract][Full Text] [Related]
29. CIITA transformation rescues the apoptotic function of MHC class II in melanoma cells. Le E; Zhang H; Blanck G Anticancer Res; 2005; 25(6B):3889-92. PubMed ID: 16312044 [TBL] [Abstract][Full Text] [Related]
30. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain. Itoh-Lindstrom Y; Piskurich JF; Felix NJ; Wang Y; Brickey WJ; Platt JL; Koller BH; Ting JP J Immunol; 1999 Sep; 163(5):2425-31. PubMed ID: 10452977 [TBL] [Abstract][Full Text] [Related]
31. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant. Zhou H; Su HS; Zhang X; Douhan J; Glimcher LH J Immunol; 1997 May; 158(10):4741-9. PubMed ID: 9144488 [TBL] [Abstract][Full Text] [Related]
32. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Satoh A; Toyota M; Ikeda H; Morimoto Y; Akino K; Mita H; Suzuki H; Sasaki Y; Kanaseki T; Takamura Y; Soejima H; Urano T; Yanagihara K; Endo T; Hinoda Y; Fujita M; Hosokawa M; Sato N; Tokino T; Imai K Oncogene; 2004 Nov; 23(55):8876-86. PubMed ID: 15467734 [TBL] [Abstract][Full Text] [Related]
33. Class II transactivator promoter activity is suppressed through regulation by a trophoblast noncoding RNA. Geirsson A; Paliwal I; Lynch RJ; Bothwell AL; Hammond GL Transplantation; 2003 Jul; 76(2):387-94. PubMed ID: 12883198 [TBL] [Abstract][Full Text] [Related]
34. Capsaicin inhibits IFN-gamma-induced MHC class II expression by suppressing transcription of class II transactivator gene in murine peritoneal macrophages. Mahmoud ME; Nikami H; Shiina T; Takewaki T; Shimizu Y Int Immunopharmacol; 2010 Jan; 10(1):86-90. PubMed ID: 19825429 [TBL] [Abstract][Full Text] [Related]
35. Class II transactivator suppresses transcription of thyroid-specific genes. Mori-Aoki A; Pietrarelli M; Nakazato M; Caturegli P; Kohn LD; Suzuki K Biochem Biophys Res Commun; 2000 Nov; 278(1):58-62. PubMed ID: 11071855 [TBL] [Abstract][Full Text] [Related]
36. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433 [TBL] [Abstract][Full Text] [Related]
37. Introduction of exogenous class II trans-activator in MHC class II-deficient ABI fibroblasts results in incomplete rescue of MHC class II antigen expression. Peijnenburg A; Gobin SJ; van Eggermond MC; Godthelp BC; van Graafeiland N; van den Elsen PJ J Immunol; 1997 Sep; 159(6):2720-7. PubMed ID: 9300692 [TBL] [Abstract][Full Text] [Related]
38. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation. Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775 [TBL] [Abstract][Full Text] [Related]
39. Revisiting the specificity of the MHC class II transactivator CIITA in vivo. Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565 [TBL] [Abstract][Full Text] [Related]
40. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Steimle V; Otten LA; Zufferey M; Mach B Cell; 1993 Oct; 75(1):135-46. PubMed ID: 8402893 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]